Research led by Baylor College of Medicine has shown that a new therapy significantly reduces triglyceride levels in individuals with mixed hyperlipidemia—elevations of triglycerides and cholesterol.

In a breakthrough for cardiovascular medicine, researchers have harnessed artificial intelligence to discover unexpected lipid-lowering effects in existing FDA-approved drugs. The study, published in ...

U.S. pharmaceutical company Eli Lilly announced on the 25th of last month (local time) interim results from Phase 1 clinical ...

Hyperlipidemia describes a condition where the amount of lipids in the blood is too high. It can include several conditions, but usually refers to a high cholesterol and triglyceride level. At healthy ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ...

Novel CRISPR-Cas9 treatments are proving effective in reversing disease for life. But ensuring their long-term safety will ...

I am looking for information on the use of inositol hexaniacinate ("no-flush niacin") in the treatment of hyperlipidemia. Most of the information I have been able to find is anecdotal. I understand ...

The role of hyperlipidemia as a risk factor for stroke is unclear. A new retrospective study has examined the relationship between a history of hyperlipidemia and MRI-defined white matter ...